Search Results - "Ernault, Etienne"

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol by Hébuterne, Xavier, Lémann, Marc, Bouhnik, Yoram, Dewit, Olivier, Dupas, Jean-Louis, Mross, Michael, D'Haens, Geert, Mitchev, Krassimir, Ernault, Étienne, Vermeire, Séverine, Brixi-Benmansour, Hedia, Moreels, Tom G, Mary, Jean-Yves, Marteau, Philippe, Colombel, Jean-Frédéric

“…To evaluate the efficacy of certolizumab pegol (CZP) in improving endoscopic lesions in patients with active ileocolonic Crohn's disease (CD). This phase IIIB…”
Get more information

Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study by Mankowski, Colette, Poole, Chris D, Ernault, Etienne, Thomas, Roger, Berni, Ellen, Currie, Craig J, Treadwell, Cecil, Calvo, José I, Plastira, Christina, Zafeiropoulou, Eirini, Odeyemi, Isaac

“…In randomised studies, the capsaicin 8% patch has demonstrated effective pain relief in patients with peripheral neuropathic pain (PNP) arising from different…”
Get full text

Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety Study by Gálvez, Rafael, Navez, Marie-Louise, Moyle, Graeme, Maihöfner, Christian, Stoker, Malcolm, Ernault, Etienne, Nurmikko, Turo J, Attal, Nadine

“…OBJECTIVES:To investigate the long-term safety and tolerability of capsaicin 8% patch repeat treatment in nondiabetic patients with peripheral neuropathic…”
Get full text

Population Pharmacokinetic Analysis of Bedaquiline‐Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study by Kurosawa, Ken, Rossenu, Stefaan, Biewenga, Jeike, Ouwerkerk‐Mahadevan, Sivi, Willems, Wouter, Ernault, Etienne, Kambili, Chrispin

“…Based on the in vitro profile of bedaquiline against mycobacterial species, it is being investigated for clinical efficacy against pulmonary nontuberculous…”
Get full text

The MOBILE Study—A Phase IIa Enriched Enrollment Randomized Withdrawal Trial to Assess the Analgesic Efficacy and Safety of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Patients with Peripheral Neuropathic Pain by Bradford, Daniel, Stirling, Anjali, Ernault, Etienne, Liosatos, Maggie, Tracy, Katherine, Moseley, Jennifer, Blahunka, Paul, Smith, Mike D

“…Abstract Objective To evaluate the analgesic efficacy and safety of ASP8477 in patients with peripheral neuropathic pain (PNP). Design Enriched enrollment…”
Get full text

Capsaicin 8% Patch Repeat Treatment in Non-diabetic Peripheral Neuropathic Pain: A 52-week, Open-label, Single-arm, Safety Study by Gálvez, Rafael, Navez, Marie-Louise, Moyle, Graeme, Maihöfner, Christian, Stoker, Malcolm, Ernault, Etienne, Nurmikko, Turo J, Attal, Nadine

“…OBJECTIVES:To investigate long-term safety and tolerability of capsaicin 8% patch repeat treatment in non-diabetic patients with peripheral neuropathic pain…”
Get full text

A Cocktail Interaction Study Evaluating the Drug‐Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels by Treijtel, Nicoline, Collins, Christiane, Bruijnsvoort, Michel, Fuhr, Rainard, Ernault, Etienne, Gangaram‐Panday, Shanti, Passier, Paul

“…ASP8477 (molecular weight 325.36 g/mol) is a fatty acid amide hydrolase inhibitor intended for the treatment of neuropathic pain. Results from in vitro studies…”
Get full text

Crohnʼs disease patients with persistently elevated CRP plasma concentration have higher rates of remission with certolizumab pegol 400 mg every 2 weeks vs every 4 weeks: P-32 by Sandborn, William J, Vermeire, Severine, Ernault, Etienne, Lichtenstein, Gary R

Get full text

Certolizumab Pegol 400 mg Rapidly Reduced the Signs and Symptoms of Crohnʼs Disease in Greek Patients Who Previously Failed Infliximab Therapy: 1150 by Triantafillidis, John, Karamanolis, Dimitrios, Kitis, Georgios, Ernault, Etienne, Mantzaris, Gerasimos

Get full text

Crohn's Disease Patients With Persistently Elevated CRP Plasma Concentration Have Higher Rates of Remission With Certolizumab Pegol 400 mg Every 2 Weeks vs. Every 4 Weeks by Sandborn, William J, Vermeire, Severine, Ernault, Etienne, Lichtenstein, Gary R

Get full text

Health-Related Quality of Life Improvements in Patients with Active Crohnʼs Disease Following Treatment with Certolizumab Pegol in the MUSIC Study (NCT00297648): 1157 by Hebuterne, Xavier, Lémann, Marc, Coteur, Geoffroy, Ernault, Etienne, Colombel, Jean-Frédéric

Get full text

Endoscopic Improvement in Patients with Active Crohnʼs Disease Treated with Certolizumab Pegol: Results of Blinded Central Reading of Recorded Endoscopies from the MUSIC Study (NCT00297648): 1154 by Hebuterne, Xavier, Lémann, Marc, Dupas, Jean-Louis, Bouhnik, Yoram, Allez, Matthieu, Louis, Edouard, Mitchev, Krassimir, Ernault, Etienne, Colombel, Jean-Frédéric

Get full text

S1030 Predictors of Response and Remission to Certolizumab Pegol in Patients With Crohn's Disease: Data From the WELCOME Study by Sandborn, William J, Abreu, Maria T, D'Haens, Geert R, Colombel, Jean-Frederic, Vermeire, Severine, Mitchev, Krassimir, Ernault, Etienne, Fedorak, Richard N, Spehlmann, Martina, Wolf, Douglas C, Lee, Scott D, Rutgeerts, Paul J

Get full text